UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027453
Receipt number R000031333
Scientific Title Effects of etelcalcetide and cinacalcet on bone mineral density in patients with secondary hyperparathyroidism
Date of disclosure of the study information 2017/05/23
Last modified on 2017/05/23 00:21:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of etelcalcetide and cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

Acronym

Effects of etelcalcetide and cinacalcet on bone mineral density

Scientific Title

Effects of etelcalcetide and cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

Scientific Title:Acronym

Effects of etelcalcetide and cinacalcet on bone mineral density

Region

Japan


Condition

Condition

Patients on hemodialysis complicated with secondary hyperparathyroidism

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effect of etelcalcetide and cinacalcet on bone mineral density.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Bone mineral density (0, 6, 12 months)
BAP, TRACP (0, 6, 12 months)

Key secondary outcomes

Ca, P, iPTH (once a month)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

etelcalcetide dosage (2.5 - 15mg/every hemodialysis session)
12 months

Interventions/Control_2

cinacalcet dosage (12.5 - 100mg/day)
12 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

Maintenance hemodialysis patients with secondary hyperparathyroidism whose iPTH levels are higher than 240pg/ml despite the administration of maxacalcitol 2.5-5 micro g/every hemodialysis session.

Key exclusion criteria

Nothing paticular.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takahiro Yajima

Organization

Matsunami general hospital

Division name

Department of nephrology

Zip code


Address

185-1, dendai, Kasamatsu-chou, Hashima-gun, Gifu

TEL

058-388-0111

Email

yajima5639@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Takahiro Yajima

Organization

Matsunami general hospital

Division name

Department of Nephrology

Zip code


Address

185-1, dendai, Kasamatsu-chou, Hashima-gun, Gifu

TEL

058-388-0111

Homepage URL


Email

yajima5639@gmail.com


Sponsor or person

Institute

Matsunami general hospital

Institute

Department

Personal name



Funding Source

Organization

Matsunami general hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 05 Month 15 Day

Date of IRB


Anticipated trial start date

2017 Year 05 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 05 Month 23 Day

Last modified on

2017 Year 05 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031333


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name